Innovations in liver cancer treatment feature prominently with University of Hong Kong researchers securing global approvals for a dual immunotherapy combining nivolumab and ipilimumab to improve survival in advanced hepatocellular carcinoma. Complementary progress includes the Princess Máxima Center pioneering comprehensive whole genome sequencing for all pediatric cancer diagnoses, enhancing precision medicine through detailed tumor DNA profiling and enabling more tailored treatment strategies in children with cancer.